https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-02-01 / J. Med. Virol. 2009 Feb;81(2):332-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-02-01 / J. Med. Virol. 2009 Feb;81(2):332-92009-02-01 00:00:002019-02-15 08:37:34In vitro use of autologous dendritic cells improves detection of T cell responses to hepatitis B virus (HBV) antigens
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-02-01 / Curr Pharm Biotechnol 2009 Feb;10(2):166-84
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-02-01 / Curr Pharm Biotechnol 2009 Feb;10(2):166-842009-02-01 00:00:002019-02-15 08:44:29Targeting the immune system in cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-02-01 / J. Immunol. 2009 Feb;182(3):1449-59
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-02-01 / J. Immunol. 2009 Feb;182(3):1449-592009-02-01 00:00:002019-02-15 08:44:31Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-02-01 / J. Immunol. 2009 Feb;182(3):1667-73
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-02-01 / J. Immunol. 2009 Feb;182(3):1667-732009-02-01 00:00:002019-02-15 08:50:59Dendritic cell-based therapeutic vaccination against myeloma: vaccine formulation determines efficacy against light chain myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-02-01 / Expert Rev Anticancer Ther 2009 Feb;9(2):199-210
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-02-01 / Expert Rev Anticancer Ther 2009 Feb;9(2):199-2102009-02-01 00:00:002009-02-01 00:00:00Hyperthermia as an adjunctive treatment for soft-tissue sarcoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-01-31 / Cancer Immunol. Immunother. 2009 Aug;58(8):1175-84
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-01-31 / Cancer Immunol. Immunother. 2009 Aug;58(8):1175-842009-01-31 00:00:002019-02-15 09:21:51The extrinsic RNA-sensing pathway for adjuvant immunotherapy of cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-01-30 / Eur. Urol. 2009 Jun;55(6):1333-42
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-01-30 / Eur. Urol. 2009 Jun;55(6):1333-422009-01-30 00:00:002021-11-15 14:46:31Vaccine therapy in patients with renal cell carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-01-28 / Liver Int. 2009 Apr;29(4):593-602
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-01-28 / Liver Int. 2009 Apr;29(4):593-6022009-01-28 00:00:002019-02-15 09:21:53Newcastle disease virus represses the activation of human hepatic stellate cells and reverses the development of hepatic fibrosis in mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-01-26 / Blood 2009 Apr;113(18):4213-23
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-01-26 / Blood 2009 Apr;113(18):4213-232009-01-26 00:00:002019-02-15 08:44:22Th-1 polarization is regulated by dendritic-cell comparison of MHC class I and class II antigens
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-01-26 / Clin. Dev. Immunol. 2008;2008:106321
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-01-26 / Clin. Dev. Immunol. 2008;2008:1063212009-01-26 00:00:002019-02-15 08:44:30Physiological role of plasmacytoid dendritic cells and their potential use in cancer immunity
